A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
A phase 2 trial of Lorlatinib in non-small-cell lung cancer and small-cell lung cancer, run by CStone Pharmaceuticals, active and no longer recruiting.
Overview
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05297890 by CStone Pharmaceuticals, with 70 participants enrolled, started 2022-05-27 and due to reach its primary completion in 2023-12-26. Interventions recorded: Lorlatinib. Conditions listed: Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialGEMSTONE-302
- IdeaSwitch drugs at maximum response, not at relapse
Shares Lorlatinib, Non-small-cell lung cancer.
- PersonJustin F. Gainor
Shares Lorlatinib, Non-small-cell lung cancer.
- TreatmentSugemalimab
- PersonD. Ross Camidge
Shares Lorlatinib, Non-small-cell lung cancer.
- PersonBenjamin Solomon
Shares Lorlatinib, Non-small-cell lung cancer.
- PersonDong-Wan Kim
Shares Lorlatinib, Non-small-cell lung cancer.
- IdeaBrain metastases included by default in every solid-tumour trial
Shares Lorlatinib, Non-small-cell lung cancer.